Tiziana Life Sciences Ltd. announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program. This follows on from previously announced positive six-month PET scan data which was presented at ECTRIMS 2023. The findings, which are summarized in table 1 below, show broad based six month improvements across various key measures for multiple sclerosis.

This kind of fatigue can significantly impact a person's daily life and functioning.